Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Cancer/Radiothérapie Année : 2018

Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations

Résumé

Considering recent phase III trials results, moderate hypofractionated radiotherapy can be considered as a standard treatment for low and intermediate risk prostate cancer management. This assessment call for a framework allowing homogeneous and reproducible practices in the different centers using this radiotherapy schedule. The French Genito-Urinary Group (GETUG) provides here recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk) and margins, dose constraints and radiotherapy techniques.
Fichier non déposé

Dates et versions

hal-01807361 , version 1 (04-06-2018)

Identifiants

Citer

J Langrand-Escure, R de Crevoisier, C Llagostera, G Créhange, G Delaroche, et al.. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations. Cancer/Radiothérapie, 2018, 22 (2), pp.193-198. ⟨10.1016/j.canrad.2017.11.004⟩. ⟨hal-01807361⟩
202 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More